Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab in Resectable Melanoma
NCT02434354Phase 1Completed
- Sponsor
- Abramson Cancer Center
- Start
- Apr 2015
- Primary completion
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in melanoma, sponsored by Abramson Cancer Center. Primary endpoint: Number of Participants (%) With CTCAE Graded Adverse Events. Started Apr 2015; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02434354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02434354.